Qlucore AB

QCORE

SE0016829824

Software

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-03 EDT			5-day change	1st Jan Change
9.25 ^SEK	0.00%		+3.35%	+20.92%

05-30	Qlucore AB Reports Earnings Results for the Full Year Ended April 30, 2024	CI
05-29	Uppsala University Hospital Chooses Qlucore AB Insights to Develop Precision Diagnostics	CI

Invitation to presentation including Q&A session of Qlucore’s year end report report for the period 1 May 2023 – 30 April 2024

May 28, 2024 at 09:01 am

Qlucore’s year end report for the period 1 May 2023 – 30 April 2024 will be published 30 May 2024.

Qlucore invites to a video and phone conference where the year end report for the period 1 May 2023 – 30 April 2024 will be presented by the CEO. After the presentationen there will be a Q&A session. The presentation will be in Swedish. Questions can be asked in English.

Date: Friday 31th of May at 10.00 am CET.
Meeting link: https://qlucore.webex.com/qlucore/j.php?MTID=m4a3c83e17aec4f21b95aae095eeffbe4
Meeting number (access code): 2732 241 3823
Password: HDimpS3aG32 (43467732 from video systems)
Join per phone: +46 85051 3563 (Sweden toll)

About Qlucore

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com

Latest news about Qlucore AB

Qlucore AB Reports Earnings Results for the Full Year Ended April 30, 2024	05-29	CI
Uppsala University Hospital Chooses Qlucore AB Insights to Develop Precision Diagnostics	05-29	CI
Qlucore Initiates Software Development Project for Cancer Diagnostics	05-27	MT
Qlucore Starts Project After Receiving EU Grant to Advance Personalized Cancer Treatment	05-27	CI
Qlucore AB Releases Unique AI-Based Solution in the Field of Lung Cancer Subtyping	05-22	CI
Qlucore Announces the Launch of the Qlucore Omics Explorer Cloud Version	04-08	CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	02-28	CI
Qlucore AB Announces Grant from EU	02-27	CI
Qlucore Submits Technical Documentation for CE Marking of Pediatric Leukemia Medical Device	01-30	MT
Qlucore Diagnostics for Pediatric Leukemia Takes A Significant Step Closer to Ce Marking	01-30	CI
Sahlgrenska Hospital Invests in Precision Diagnostics with Qlucore AB Insights	01-16	CI
Boehringer Ingelheim Signs Two-Year Agreement with Qlucore	01-11	CI
Qlucore Announces Swedish Innovation Evaluated for Clinical Diagnosis of Pediatric Leukemia	12-13	CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	11-28	CI
Qlucore AB Appoints Lars Höckenström as A Member of the Board of Directors	23-09-07	CI
Qlucore AB Reports Earnings Results for the First Quarter Ended July 31, 2023	23-08-30	CI
Qlucore AB Reports Earnings Results for the Fourth Quarter Ended April 30, 2023	23-05-31	CI
Qlucore AB Reports Earnings Results for the Full Year Ended April 30, 2023	23-05-31	CI
Qlucore Launches Qlucore Omics Explorer Version 3.9	23-04-26	CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-02-28	CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-11-28	CI
Qlucore Software Used in New Project to Prevent Cardiovascular Diseases	22-11-17	CI
Qlucore Receives Patent in Europe	22-09-26	CI
Qlucore Ab Reports Earnings Results for the First Quarter Ended July 31, 2022	22-08-30	CI
Qlucore to Develop Diagnostics Product for Two Blood Cancer Types	22-08-26	MT

Chart Qlucore AB

Duration

Period

More charts

Company Profile

Qlucore AB is a Sweden-based provider of new generation of intuitive bioinformatics software for research and precision and companion diagnostics. Its mission is to make it easier to analyze the vast amounts of complex data generated by innovations in genomics and proteomics. This is done by providing visualization-based analysis data tools for bioinformatics for research and precision diagnostics. The tools are so easy to use that researchers, technicians and doctors can easily interpret and explore their data sets. Qlucore Diagnostics software is a platform for multi-omics companion and precision diagnostics. AI-driven, disease-specific machine learning-based classification models are combined with patient-friendly visualizations in an easy-to-use and cost-effective software solution that integrates with a wide range of data-generating technologies and instruments. Qlucore was founded in 2007 by researchers at the departments of mathematics and clinical genetics at Lund University.

Sector

Software

Calendar

2024-08-27 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Software

	1st Jan change	Capi.
QLUCORE AB	+20.92%	3.51M
MICROSOFT CORPORATION	+22.53%	3,414B
SYNOPSYS INC.	+17.88%	93.41B
CADENCE DESIGN SYSTEMS, INC.	+15.82%	86.85B
PALANTIR TECHNOLOGIES INC.	+50.55%	57.52B
DASSAULT SYSTÈMES SE	-20.29%	48.67B
THE TRADE DESK, INC.	+38.23%	48.1B
ATLASSIAN CORPORATION	-23.39%	47.45B
SEA LIMITED	+76.52%	40.4B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-4.63%	27.06B